Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

Alteogen Submits Application for Biosimilar Aflibercept in Korea

Sep 13, 2024

On 13 September 2024, Korea Biomedical Review reported that Korea-based Alteogen has submitted a domestic marketing authorisation application for its ALT-L9, biosimilar to Regeneron’s Eylea® (aflibercept), for treatment of nAMD.

This follows Alteogen’s subsidiary, Altos Biologics’, MAA submission to the EMA in July 2024 for ALT-L9, with marketing approval expected in 2025.  Altos Biologics completed enrolment in its phase 3 trials of ALT-L9 in patients with nAMD in February 2023.  The trials reportedly demonstrated therapeutic equivalence between ALT-L9 and Eylea®.

The first aflibercept biosimilar approved in Korea was Samsung Bioepis’ Afilivu® in February 2024, which is being marketed by Samil Pharmaceutical.  Celltrion’s Eydenzelt™  (CT-P42) (aflibercept) received Korean approval in May 2024.